TY - JOUR
T1 - Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer
T2 - how to treat and when?
AU - Schoenmaekers, Janna Josephus Anna Oda
AU - Paats, Marthe Sentijna
AU - Dingemans, Anne-Marie Clasina
AU - Hendriks, Lizza Elisabeth Lucia
PY - 2020/12
Y1 - 2020/12
KW - Non-small cell lung cancer (NSCLC)
KW - central nervous system metastases (CNS metastases)
KW - oligometastatic disease
KW - tyrosine kinase inhibitors (TKIs)
KW - DABRAFENIB PLUS TRAMETINIB
KW - POSITIVE SOLID TUMORS
KW - EML4-ALK FUSION GENE
KW - HIGH-DOSE ERLOTINIB
KW - BRAIN METASTASES
KW - OPEN-LABEL
KW - EGFR-MUTATION
KW - LEPTOMENINGEAL METASTASES
KW - CEREBROSPINAL-FLUID
KW - 1ST-LINE TREATMENT
U2 - 10.21037/tlcr-20-459
DO - 10.21037/tlcr-20-459
M3 - Review article
C2 - 33489821
VL - 9
SP - 2599
EP - 2617
JO - Translational Lung Cancer Research
JF - Translational Lung Cancer Research
SN - 2226-4477
IS - 6
ER -